Alexion Pharmaceuticals, Inc. (ALXN)
(Delayed Data from NSDQ)
$136.69 USD
+3.56 (2.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $136.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$136.69 USD
+3.56 (2.67%)
Updated May 3, 2019 04:00 PM ET
After-Market: $136.70 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Alexion Pharmaceuticals (ALXN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) closed at $86.14 in the latest trading session, marking a +1.98% move from the prior day.
Alexion Pharmaceuticals (ALXN) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Alexion Pharmaceuticals (ALXN) closed the most recent trading day at $82.50, moving +0.17% from the previous trading session.
Alexion (ALXN) Down 6.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Alexion (ALXN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Can Biotech ETFs Gain on Mixed Q4 Earnings Results?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.
Western Union (WU) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Western Union (WU) delivered earnings and revenue surprises of -11.63% and -1.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
VAREX IMAGING (VREX) Q1 Earnings Miss Estimates
by Zacks Equity Research
VAREX IMAGING (VREX) delivered earnings and revenue surprises of -25.00% and 4.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Diodes (DIOD) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Diodes (DIOD) delivered earnings and revenue surprises of 3.17% and 0.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Top Ranked Growth Stocks to Buy for February 4th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, February 4th
Vertex (VRTX) Q4 Earnings Beat on Solid CF Product Sales
by Zacks Equity Research
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
Top Ranked Growth Stocks to Buy for January 31st
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, January 31st.
Alexion (ALXN) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Alexion (ALXN) beats on earnings and revenues in the fourth quarter of 2019.
Alexion Pharmaceuticals (ALXN) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Alexion (ALXN) delivered earnings and revenue surprises of 3.44% and 1.72%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Big Drug/Biotech Stock Earnings on Jan 30: BIIB, ALXN & More
by Zacks Equity Research
Let us take a look at five big drug/biotech companies due to release their quarterly results on Jan 30.
Why Earnings Season Could Be Great for Alexion (ALXN)
by Zacks Equity Research
Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Top Ranked Growth Stocks to Buy for January 29th
by Zacks Equity Research
Here are three stocks with buy ranks and strong growth characteristics for investors to consider today, January 29th.
Acceleron (XLRN) Up on Success of PAH Drug in Phase II Study
by Zacks Equity Research
Acceleron (XLRN) stock surges as sotatercept meets primary and secondary endpoints in a phase II study in patients with pulmonary arterial hypertension.
Can CF Drugs Drive Growth for Vertex (VRTX) in Q4 Earnings?
by Zacks Equity Research
On Vertex's (VRTX) fourth-quarter earnings call, investor focus will be on the sales uptake of its CF drugs and the unveiling plans for the newly-approved Trikafta triple combination regimen.
The Zacks Analyst Blog Highlights: Lear, SEI Investments, Alexion Pharmaceuticals and Apartment Investment and Management
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Lear, SEI Investments, Alexion Pharmaceuticals and Apartment Investment and Management
Will Soliris, Ultomiris Drive Alexion's (ALXN) Q4 Earnings?
by Zacks Equity Research
Alexion Inc.'s (ALXN) fourth-quarter 2019 results, scheduled to be reported on Jan 30, are likely to reflect solid performance of key drugs.
Amgen (AMGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While Amgen's (AMGN) drugs like Prolia & Xgeva are expected to have done well, slowdown in sales of mature products are likely to have weighed on fourth-quarter sales.
Will Lower Revenues Dampen Corning's (GLW) Q4 Earnings?
by Zacks Equity Research
Corning's (GLW) fourth-quarter performance is likely to have been hurt by changing market conditions that translated into lower sales at Optical Communications and Display Technologies segments.
Can Biogen (BIIB) Keep the Earnings Streak Alive in Q4?
by Zacks Equity Research
Biogen's (BIIB) fourth-quarter MS franchise sales are expected to have been flat. Spinraza U.S. sales are expected to have been supported by continued patient growth.
Tesla's (TSLA) Unintended Acceleration Problem
by Sejuti Banerjea
A fresh lawsuit for unintended acceleration increase chances of a broader product recall.
Epizyme Gets FDA Nod for Lead Drug in Epithelioid Sarcoma
by Zacks Equity Research
Epizyme (EPZM) gets a significant boost with the approval of Tazverik (tazemetostat) for the treatment of metastatic or locally advanced epithelioid sarcoma.